Publications:

---

EML4-ALK biology and drug resistance in Non-Small Cell Lung Cancer: a new phase of discoveries.

Molecular Oncology

Elshatlawy, Mariam M; Sampson, Josephina J; Clarke, Katy K; Bayliss, Richard R

Publication Date: 2023-05-07

Variant appearance in text: ALK: L1198F

PubMed Link: 37149843

Variant Present in the following documents:

• Main text
• MOL2-17-950.pdf

View BVdb publication page

---

Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review.

Translational Lung Cancer Research

Desai, Aakash A; Lovly, Christine M CM

Publication Date: 2023-03-31

Variant appearance in text: ALK: L1198F

PubMed Link: 37057106

Variant Present in the following documents:

• Main text
• tlcr-12-03-615.pdf

View BVdb publication page

---

Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs.

International Journal Of Molecular Sciences

Cheon, So Yeong SY; Kwon, Sunghark S

Publication Date: 2023-03-18

Variant appearance in text: ALK: L1198F

PubMed Link: 36982897

Variant Present in the following documents:

• Main text
• ijms-24-05821.pdf

View BVdb publication page

---

MetalProGNet: a structure-based deep graph model for metalloprotein-ligand interaction predictions.

Chemical Science

Jiang, Dejun D; Ye, Zhaofeng Z; Hsieh, Chang-Yu CY; Yang, Ziyi Z; Zhang, Xujun X; Kang, Yu Y; Du, Hongyan H; Wu, Zhenxing Z; Wang, Jike J; Zeng, Yundian Y; Zhang, Haotian H; Wang, Xiaorui X; Wang, Mingyang M; Yao, Xiaojun X; Zhang, Shengyu S; Wu, Jian J; Hou, Tingjun T

Publication Date: 2023-02-22

Variant appearance in text: ALK: L1198F

PubMed Link: 36845922

Variant Present in the following documents:

• SC-014-D2SC06576B-s003.xlsx, sheet 1

View BVdb publication page

---

Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.

Molecular Biomedicine

Wang, Zixi Z; Xing, Yurou Y; Li, Bingjie B; Li, Xiaoyu X; Liu, Bin B; Wang, Yongsheng Y

Publication Date: 2022-12-12

Variant appearance in text: ALK: L1198F

PubMed Link: 36508072

Variant Present in the following documents:

• Main text
• 43556_2022_Article_107.pdf

View BVdb publication page

---

Molecular targeted therapy for anticancer treatment.

Experimental & Molecular Medicine

Min, Hye-Young HY; Lee, Ho-Young HY

Publication Date: 2022-10

Variant appearance in text: ALK: L1198F

PubMed Link: 36224343

Variant Present in the following documents:

• Main text
• 12276_2022_Article_864.pdf

View BVdb publication page

---

Crizotinib attenuates cancer metastasis by inhibiting TGFβ signaling in non-small cell lung cancer cells.

Experimental & Molecular Medicine

Park, Soonbum S; Cho, Eun A EA; Chun, Jung Nyeo JN; Lee, Da Young DY; Lee, Sanghoon S; Kim, Mi Yeon MY; Bae, Sang Mun SM; Jo, Su In SI; Lee, So Hee SH; Park, Hyun Ho HH; Kim, Tae Min TM; So, Insuk I; Kim, Sang-Yeob SY; Jeon, Ju-Hong JH

Publication Date: 2022-08

Variant appearance in text: ALK: L1198F

PubMed Link: 35999455

Variant Present in the following documents:

• 12276_2022_835_MOESM1_ESM.pdf

View BVdb publication page

---

Anaplastic lymphoma kinase-special immunity and immunotherapy.

Frontiers In Immunology

Guo, Ye Y; Guo, Hanfei H; Zhang, Yongfei Y; Cui, Jiuwei J

Publication Date: 2022

Variant appearance in text: ALK: L1198F

PubMed Link: 35958559

Variant Present in the following documents:

• Main text
• fimmu-13-908894.pdf

View BVdb publication page

---

Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.

Cancer Science

Sakashita, Takuya T; Yanagitani, Noriko N; Koike, Sumie S; Low, Siew-Kee SK; Takagi, Satoshi S; Baba, Satoko S; Takeuchi, Kengo K; Nishio, Makoto M; Fujita, Naoya N; Katayama, Ryohei R

Publication Date: 2022-11

Variant appearance in text: ALK: L1198F

PubMed Link: 35950895

Variant Present in the following documents:

• CAS-113-3888.pdf
• CAS-113-3888-s002.pdf

View BVdb publication page

---

AACR Project GENIE: 100,000 Cases and Beyond.

Cancer Discovery

Pugh, Trevor J TJ; Bell, Jonathan L JL; Bruce, Jeff P JP; Doherty, Gary J GJ; Galvin, Matthew M; Green, Michelle F MF; Hunter-Zinck, Haley H; Kumari, Priti P; Lenoue-Newton, Michele L ML; Li, Marilyn M MM; Lindsay, James J; Mazor, Tali T; Ovalle, Andrea A; Sammut, Stephen-John SJ; Schultz, Nikolaus N; Yu, Thomas V TV; Sweeney, Shawn M SM; Bernard, Brady B; ,

Publication Date: 2022-09-02

Variant appearance in text: ALK: L1198F

PubMed Link: 35819403

Variant Present in the following documents:

• cd-21-1547_supplementary_table_1_suppst1.xlsx, sheet 1

View BVdb publication page

---

Targeting ALK Rearrangements in NSCLC: Current State of the Art.

Frontiers In Oncology

Peng, Ling L; Zhu, Liping L; Sun, Yilan Y; Stebbing, Justin J; Selvaggi, Giovanni G; Zhang, Yongchang Y; Yu, Zhentao Z

Publication Date: 2022

Variant appearance in text: ALK: L1198F

PubMed Link: 35463328

Variant Present in the following documents:

• Main text
• fonc-12-863461.pdf

View BVdb publication page

---

Successful treatment of refractory brain metastases from ALK-positive lung cancer with lorlatinib.

Thoracic Cancer

Nakagawa, Yoshiko Y; Shimizu, Tetsuo T; Hiranuma, Hisato H; Gon, Yasuhiro Y

Publication Date: 2022-05

Variant appearance in text: ALK: L1198F

PubMed Link: 35373538

Variant Present in the following documents:

• Main text
• TCA-13-1431.pdf

View BVdb publication page

---

Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report.

Frontiers In Oncology

Wang, Zhan Z; Geng, Yan Y; Yuan, Ling-Yan LY; Wang, Miao-Miao MM; Ye, Chen-Yang CY; Sun, Li L; Dai, Wei-Ping WP; Zang, Yuan-Sheng YS

Publication Date: 2022

Variant appearance in text: ALK: L1198F

PubMed Link: 35237506

Variant Present in the following documents:

• fonc-12-761558.pdf

View BVdb publication page

---

Systematic review and meta-analysis of genomic alterations in acral melanoma.

Pigment Cell & Melanoma Research

Broit, Natasa N; Johansson, Peter A PA; Rodgers, Chloe B CB; Walpole, Sebastian T ST; Hayward, Nicholas K NK; Pritchard, Antonia L AL

Publication Date: 2022-05

Variant appearance in text: ALK: L1198F

PubMed Link: 35229492

Variant Present in the following documents:

• PCMR-35-369-s003.xlsx, sheet 12

View BVdb publication page

---

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

Nature Cancer

Tamborero, David D; Dienstmann, Rodrigo R; Rachid, Maan Haj MH; Boekel, Jorrit J; Lopez-Fernandez, Adria A; Jonsson, Markus M; Razzak, Ali A; Braña, Irene I; De Petris, Luigi L; Yachnin, Jeffrey J; Baird, Richard D RD; Loriot, Yohann Y; Massard, Christophe C; Martin-Romano, Patricia P; Opdam, Frans F; Schlenk, Richard F RF; Vernieri, Claudio C; Masucci, Michele M; Villalobos, Xenia X; Chavarria, Elena E; , ; Balmaña, Judith J; Apolone, Giovanni G; Caldas, Carlos C; Bergh, Jonas J; Ernberg, Ingemar I; Fröhling, Stefan S; Garralda, Elena E; Karlsson, Claes C; Tabernero, Josep J; Voest, Emile E; Rodon, Jordi J; Lehtiö, Janne J

Publication Date: 2022-02

Variant appearance in text: ALK: Leu1198Phe

PubMed Link: 35221333

Variant Present in the following documents:

• 43018_2022_332_MOESM3_ESM.xlsx, sheet 1

View BVdb publication page

---

Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer.

Translational Cancer Research

Vavalà, Tiziana T; Mariniello, Annapaola A; Novello, Silvia S

Publication Date: 2019-01

Variant appearance in text: ALK: L1198F

PubMed Link: 35117063

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib.

Clinical Pharmacology : Advances And Applications

Rijavec, Erika E; Biello, Federica F; Indini, Alice A; Grossi, Francesco F; Genova, Carlo C

Publication Date: 2022

Variant appearance in text: ALK: L1198F

PubMed Link: 35082536

Variant Present in the following documents:

• Main text
• cpaa-14-1.pdf

View BVdb publication page

---

Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase.

Frontiers In Cell And Developmental Biology

Liang, Shuai S; Wang, Qing Q; Qi, Xuesen X; Liu, Yudi Y; Li, Guozhen G; Lu, Shaoyong S; Mou, Linkai L; Chen, Xiangyu X

Publication Date: 2021

Variant appearance in text: ALK: L1198F

PubMed Link: 35004700

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.

Medcomm

Cheng, Yuan Y; Zhang, Tao T; Xu, Qing Q

Publication Date: 2021-12

Variant appearance in text: ALK: L1198F

PubMed Link: 34977873

Variant Present in the following documents:

• Main text
• MCO2-2-692.pdf

View BVdb publication page

---

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Cancers

Hare, Lucy L; Burke, G A Amos GAA; Turner, Suzanne D SD

Publication Date: 2021-11-29

Variant appearance in text: ALK: L1198F

PubMed Link: 34885113

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Cancers

Hare, Lucy L; Burke, G A Amos GAA; Turner, Suzanne D SD

Publication Date: 2021-11-29

Variant appearance in text: ALK: L1198F

PubMed Link: 34885113

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Liquid biopsy: Novel perspectives on the importance and spectrum of PIK3CA, PTEN and RET mutations in solid tumors.

Molecular And Clinical Oncology

Sahin, Ibrahim I; Saat, Hanife H; Aksoy, Sercan S; Dizdar, Omer O; Erdem, Haktan Bagis HB; Bahsi, Taha T

Publication Date: 2022-01

Variant appearance in text: ALK: L1198F

PubMed Link: 34824841

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis-targeting chimeras.

Medcomm

Song, Xiaoling X; Zhong, Hui H; Qu, Xiaojuan X; Yang, Linsong L; Jiang, Biao B

Publication Date: 2021-09

Variant appearance in text: ALK: L1198F

PubMed Link: 34766150

Variant Present in the following documents:

• Main text
• MCO2-2-341.pdf

View BVdb publication page

---

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.

Frontiers In Oncology

Pan, Yue Y; Deng, Chao C; Qiu, Zhenhua Z; Cao, Chenghui C; Wu, Fang F

Publication Date: 2021

Variant appearance in text: ALK: L1198F

PubMed Link: 34660278

Variant Present in the following documents:

• Main text
• fonc-11-713530.pdf

View BVdb publication page

---

Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.

Frontiers In Endocrinology

Hescheler, Daniel A DA; Riemann, Burkhard B; Hartmann, Milan J M MJM; Michel, Maximilian M; Faust, Michael M; Bruns, Christiane J CJ; Alakus, Hakan H; Chiapponi, Costanza C

Publication Date: 2021

Variant appearance in text: ALK: L1198F

PubMed Link: 34630336

Variant Present in the following documents:

• Table_1.xlsx, sheet 2

View BVdb publication page

---

A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review.

Jto Clinical And Research Reports

Zhu, Viola W VW; Nagasaka, Misako M; Madison, Russell R; Schrock, Alexa B AB; Cui, Jean J; Ou, Sai-Hong Ignatius SI

Publication Date: 2021-01

Variant appearance in text: ALK: L1198F

PubMed Link: 34589977

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy.

Cancers

Rodak, Olga O; Peris-Díaz, Manuel David MD; Olbromski, Mateusz M; Podhorska-Okołów, Marzenna M; Dzięgiel, Piotr P

Publication Date: 2021-09-20

Variant appearance in text: ALK: L1198F

PubMed Link: 34572931

Variant Present in the following documents:

• Main text
• cancers-13-04705.pdf

View BVdb publication page

---

Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy.

Gynecologic Oncology Reports

Kyi, Chrisann C; Friedman, Claire F CF; Mueller, Jennifer J JJ; Benayed, Ryma R; Ladanyi, Marc M; Arcila, Maria M; Yang, Soo Ryum SR; Hensley, Martee L ML; Chiang, Sarah S

Publication Date: 2021-08

Variant appearance in text: ALK: L1198F

PubMed Link: 34522753

Variant Present in the following documents:

• main.pdf

View BVdb publication page

---

Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?

Translational Oncology

Ou, Sai-Hong Ignatius SI; Nagasaka, Misako M; Brazel, Danielle D; Hou, Yujie Y; Zhu, Viola W VW

Publication Date: 2021-11

Variant appearance in text: ALK: L1198F

PubMed Link: 34365220

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma.

Respiratory Medicine Case Reports

Von, Cheong E CE; Fuang, Ho Gwo HG

Publication Date: 2021

Variant appearance in text: ALK: L1198F

PubMed Link: 34336591

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma.

Cold Spring Harbor Molecular Case Studies

Liu, Tingting T; Merguerian, Matthew D MD; Rowe, Steven P SP; Pratilas, Christine A CA; Chen, Allen R AR; Ladle, Brian H BH

Publication Date: 2021-08

Variant appearance in text: ALK: L1198F

PubMed Link: 34210658

Variant Present in the following documents:

• Main text
• MCS006064Liu.pdf

View BVdb publication page

---

TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations.

Molecular Cancer Therapeutics

Murray, Brion W BW; Zhai, Dayong D; Deng, Wei W; Zhang, Xin X; Ung, Jane J; Nguyen, Vivian V; Zhang, Han H; Barrera, Maria M; Parra, Ana A; Cowell, Jessica J; Lee, Dong J DJ; Aloysius, Herve H; Rogers, Evan E

Publication Date: 2021-09

Variant appearance in text: ALK: L1198F

PubMed Link: 34158340

Variant Present in the following documents:

• Main text
• 1499.pdf

View BVdb publication page

---

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia-a case report.

Respirology Case Reports

Sasaki, Kota K; Yokota, Yusuke Y; Isojima, Toshihito T; Fujii, Mayumi M; Hasui, Kengo K; Chen, Yu Y; Saito, Kensuke K; Takahata, Takenori T; Kindaichi, Seiko S; Sato, Atsushi A

Publication Date: 2021-07

Variant appearance in text: ALK: L1198F

PubMed Link: 34123384

Variant Present in the following documents:

• Main text

View BVdb publication page

---

A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma.

Journal Of Experimental & Clinical Cancer Research : Cr

Mlakar, Vid V; Morel, Edouard E; Mlakar, Simona Jurkovic SJ; Ansari, Marc M; Gumy-Pause, Fabienne F

Publication Date: 2021-06-08

Variant appearance in text: ALK: L1198F

PubMed Link: 34103089

Variant Present in the following documents:

• Main text

View BVdb publication page

---

An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance.

Bosnian Journal Of Basic Medical Sciences

Patcas, Adela A; Chis, Ana Florica AF; Militaru, Claudia Florentina CF; Bordea, Ioana Roxana IR; Rajnoveanu, Ruxandra R; Coza, Ovidiu Florin OF; Hanna, Reem R; Tiberiu, Tamas T; Todea, Doina Adina DA

Publication Date: 2022-02-01

Variant appearance in text: ALK: L1198F

PubMed Link: 34082691

Variant Present in the following documents:

• Main text
• BJBMS-22-1.pdf

View BVdb publication page

---

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Signal Transduction And Targeted Therapy

Zhong, Lei L; Li, Yueshan Y; Xiong, Liang L; Wang, Wenjing W; Wu, Ming M; Yuan, Ting T; Yang, Wei W; Tian, Chenyu C; Miao, Zhuang Z; Wang, Tianqi T; Yang, Shengyong S

Publication Date: 2021-05-31

Variant appearance in text: ALK: L1198F

PubMed Link: 34054126

Variant Present in the following documents:

• Main text
• 41392_2021_Article_572.pdf

View BVdb publication page

---

Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer.

Cancers

Gregorc, Vanesa V; Lazzari, Chiara C; Mandalá, Mario M; Ippati, Stefania S; Bulotta, Alessandra A; Cangi, Maria Giulia MG; Khater, Abdelrahman A; Viganò, Maria Grazia MG; Mirabile, Aurora A; Pecciarini, Lorenza L; Ogliari, Francesca Rita FR; Arrigoni, Gianluigi G; Grassini, Greta G; Veronesi, Giulia G; Doglioni, Claudio C

Publication Date: 2021-04-22

Variant appearance in text: ALK: L1198F

PubMed Link: 33922215

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.

Nature Communications

Mizuta, Hayato H; Okada, Koutaroh K; Araki, Mitsugu M; Adachi, Jun J; Takemoto, Ai A; Kutkowska, Justyna J; Maruyama, Kohei K; Yanagitani, Noriko N; Oh-Hara, Tomoko T; Watanabe, Kana K; Tamai, Keiichi K; Friboulet, Luc L; Katayama, Kazuhiro K; Ma, Biao B; Sasakura, Yoko Y; Sagae, Yukari Y; Kukimoto-Niino, Mutsuko M; Shirouzu, Mikako M; Takagi, Satoshi S; Simizu, Siro S; Nishio, Makoto M; Okuno, Yasushi Y; Fujita, Naoya N; Katayama, Ryohei R

Publication Date: 2021-02-24

Variant appearance in text: ALK: L1198F

PubMed Link: 33627640

Variant Present in the following documents:

• Main text
• 41467_2021_21396_MOESM1_ESM.pdf
• 41467_2021_21396_MOESM2_ESM.pdf
• 41467_2021_Article_21396.pdf

View BVdb publication page

---

Therapeutic Sequencing in ALK+ NSCLC.

Pharmaceuticals (Basel, Switzerland)

Elsayed, Mei M; Christopoulos, Petros P

Publication Date: 2021-01-21

Variant appearance in text: ALK: L1198F

PubMed Link: 33494549

Variant Present in the following documents:

• Main text
• pharmaceuticals-14-00080.pdf

View BVdb publication page

---

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies.

Translational Lung Cancer Research

Russo, Alessandro A; Cardona, Andrés F AF; Caglevic, Christian C; Manca, Paolo P; Ruiz-Patiño, Alejandro A; Arrieta, Oscar O; Rolfo, Christian C

Publication Date: 2020-12

Variant appearance in text: ALK: L1198F

PubMed Link: 33489820

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won.

Translational Lung Cancer Research

Tabbò, Fabrizio F; Reale, Maria Lucia ML; Bironzo, Paolo P; Scagliotti, Giorgio V GV

Publication Date: 2020-12

Variant appearance in text: ALK: L1198F

PubMed Link: 33489817

Variant Present in the following documents:

• Main text

View BVdb publication page

---